Discontinuation report MYLAN-RANITIDINE
| Report ID | 6808 |
| Drug Identification Number | 02207761 |
| Brand name | MYLAN-RANITIDINE |
| Common or Proper name | RANITIDINE |
| Company Name | MYLAN PHARMACEUTICALS ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RANITIDINE |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 and 500 |
| ATC code | A02BA |
| ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2017-04-12 |
| Remaining supply date | 2017-04-10 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2017-04-13 | French | Compare |
| v1 | 2017-04-13 | English | Compare |
Showing 1 to 2 of 2